Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology*; D000818:Animals; D005020:Ethyl Methanesulfonate / Q000627:therapeutic use; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology*; D012515:Mast-Cell Sarcoma / Q000188:drug therapy; D008769:Methylnitronitrosoguanidine / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009153:Mutagens / Q000627:therapeutic use*; D010042:Ouabain / Q000494:pharmacology; D013866:Thioguanine / Q000494:pharmacology
D009153:Mutagens; D008769:Methylnitronitrosoguanidine; D010042:Ouabain; D005020:Ethyl Methanesulfonate; D013866:Thioguanine